Direct Rx Duloxetine D/R recalled for N-nitroso impurity above FDA limit
Direct Rx's packaged Duloxetine D/R 30 mg capsules contain levels of N-nitroso-duloxetine, a potentially harmful impurity, above FDA's recommended limit. This is a manufacturing quality issue affecting specific lots distributed nationwide.
From the FDA notice · Read the official notice ↗
What to do
- Check your Duloxetine D/R bottle for lot numbers 09JA2530, 31JA2507, 09DE2412, 09JA2528, or 29JA2511 (all expire 04/30/2027)
- Contact your pharmacist or doctor if you have one of the affected lots
- Do not stop taking your medication without talking to your doctor first
Is yours affected?
Compare your label or packaging with the recalled product.
- Product
- DULOXETINE D/R, a) 30 mg (NDC 61919-482-30), 30 Caps; b) 30 mg (NDC 61919-482-60), 60 Caps; CYMBALTA, Packaged and Distributed by Direct Rx.
- Sold in
- Nationwide
- Made for
- Adults
Details
- Units affected
- 263 Bottles
- Illnesses reported
- None reported
- Manufactured in
- 94 Worldwide Dr, N/A, Dawsonville, GA, United States
- Classification
- Class II
- Recall number
- D-0617-2026
In the FDA's words
- Description
- DULOXETINE D/R, a) 30 mg (NDC 61919-482-30), 30 Caps; b) 30 mg (NDC 61919-482-60), 60 Caps; CYMBALTA, Packaged and Distributed by Direct Rx. CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit Lot: a) 09JA2530, 31JA2507, expires: 04/30/2027; b) Lot: 09DE2412, 09JA2528, 29JA2511, expires: 04/30/2027. Distribution: U.S. Nationwide Affected quantity: 263 Bottles
- Hazard
- CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
More from Direct Rx
- Direct Rx lidocaine ointment recalled for subpotent drug strength
ModerateFDAOct 29, 2026